Current Issues of Targeted Therapy of Polycythemia Vera

The issues of therapy response criteria, first-line hydroxycarbamide intolerance and resistance to it as well as early changes in treatment strategy remain controversial and debatable in the management of polycythemia vera patients. The review outlines the results of literature data analysis related to the estimation of first-line therapy efficacy, it considers the spectrum and frequency of adverse events of hydroxycarbamide treatment, and focuses on the experience of using ruxolitinib, JAK2 inhibitor. The review provides results, including the long-term ones, of the comparative analysis of ruxolitinib use and the best available therapy of polycythemia vera patients with hydroxycarbamide resistance. The present review uses the materials of expert panel with the participation of Prof. Giuseppe A. Palumbo (University of Catania, Sicily, Italy) held on June 7, 2020.

• Anait Levonovna Melikyan National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 ; ФГБУ «НМИЦ гематологии» Минздрава России, Новый Зыковский пр-д, д. 4, Москва, Российская Федерация, 125167
• I.N. Subortseva National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 ; ФГБУ «НМИЦ гематологии» Минздрава России, Новый Зыковский пр-д, д. 4, Москва, Российская Федерация, 125167

1. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014;59(4):31–56.
2. [Melikyan AL, Turkina AG, Abdulkadyrov KM, et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis). Gematologiya i transfuziologiya. 2014;59(4):31–56. (In Russ)]
3. Меликян А.Л., Туркина А.Г., Ковригина А.М. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017;62(1):25–60.
4. [Melikyan AL, Turkina AG, Kovrigina AM, et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologiya i transfuziologiya. 2017;62(1):25–60. (In Russ)]
5. Меликян А.Л., Ковригина А.М., Суборцева И.Н. и др. Национальные клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2018 г.) Гематология и трансфузиология. 2018;63(3):275–315. doi: 10.25837/HAT.2019.51.88.001.
6. [Melikyan AL, Kovrigina AM, Subortseva IN, et al. National clinical recommendations for diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2018). Gematologiya i transfuziologiya. 2018;63(3):275–315. doi: 10.25837/HAT.2019.51.88.001. (In Russ)]
7. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544. DOI: https://doi.org/10.1182/blood-2016-03-643544
8. Танашян М.М., Кузнецова П.И., Лагода О.В. и др. Миелопролиферативные заболевания и ишемический инсульт. Анналы клинической и экспериментальной неврологии. 2014;8(2):41–5.
9. [Tanashyan MM, Kuznetsova PI, Lagoda OV, et al. Myeloproliferative diseases and ischemic stroke. Annaly klinicheskoi i eksperimental’noi nevrologii. 2014;8(2):41–5. (In Russ)]
10. Танашян М.М., Кузнецова П.И., Суборцева И.Н. и др. Хроническая и острая цереброваскулярная патология при Ph-негативных миелопролиферативных заболеваниях. Гематология и трансфузиология. 2016;61(3):146–50. doi: 18821/0234-5730-2016-61-3-146-150.
11. [Tanashyan MM, Kuznetsova PI, Subortseva IN, et al. Chronic and acute cerebrovascular pathology in patients with Ph-negative myeloproliferative diseases. Gematologiya i transfuziologiya. 2016;61(3):146–50. doi: 10.18821/0234-5730-2016-61-3-146-150. (In Russ)]
12. Меликян А.Л., Суборцева И.Н., Суханова Г.А. Тромбогеморрагические осложнения у больных Ph-негативными миелопролиферативными заболеваниями. Кровь. 2014;2(18):21–5.
13. [Melikyan AL, Subortseva IN, Sukhanova GA. Thrombohemorrhagic complications in patients with Ph-negative myeloproliferative diseases. Krov’. 2014;2(18):21–5. (In Russ)]
14. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И. и др. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412. DOI: https://doi.org/10.21320/2500-2139-2015-8-4-397-412
15. [Subortseva IN, Kolosheinova TI, Pustovaya EI, et al. Polycythemia Vera: Literature Review and Own Data. Clinical oncohematology. 2015;8(4):397–412. doi: 10.21320/2500-2139-2015-8-4-397-412. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2015-8-4-397-412
16. Falchi L, Newberry KJ, Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myel Leuk. 2015;15:27–33. doi: 10.1016/j.clml.2015.02.013. DOI: https://doi.org/10.1016/j.clml.2015.02.013
17. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81. doi: 10.1182/blood-2013-01-478891. DOI: https://doi.org/10.1182/blood-2013-01-478891
18. Меликян А.Л., Суборцева И.Н., Шуваев В.А. и др. Современный взгляд на диагностику и лечение классических Ph-негативных миелопролиферативных заболеваний. Клиническая онкогематология. 2021;14(1):129–37. doi: 10.21320/2500-2139-2021-14-1-129-137. DOI: https://doi.org/10.21320/2500-2139-2021-14-1-129-137
19. [Melikyan AL, Subortseva IN, Shuvaev VA, et al. Current View on Diagnosis and Treatment of Classical Ph-Negative Myeloproliferative Neoplasms. Clinical oncohematology. 2021;14(1):129–37. doi: 10.21320/2500-2139-2021-14-1-129-137. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2021-14-1-129-137
20. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829–33. doi: 10.1182/blood-2008-09-176818. DOI: https://doi.org/10.1182/blood-2008-09-176818
21. Palandri F, Elli ME, Benevolo G, et al. Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood. 2019;134(1):4174. doi: 10.1182/blood-2019-125388. DOI: https://doi.org/10.1182/blood-2019-125388
22. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961–3. doi: 10.1111/j.1365-2141.2009.08019.x. DOI: https://doi.org/10.1111/j.1365-2141.2009.08019.x
23. Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, et al.; Grupo Espanol de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786–93. doi: 10.1111/bjh.13886. DOI: https://doi.org/10.1111/bjh.13886
24. Kiladjian J-J, Pierre Z, Masayuki H, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):е226–е doi: 10.1016/S2352-3026(19)30207-8. DOI: https://doi.org/10.1016/S2352-3026(19)30207-8
25. Alvarez-Larran A, Verstovsek S, Perez-Encinas M, et al. Comparison of ruxolitinib and real-world best available therapy in terms of overall survival and thrombosis in patients with polycythemia vera who are resistant or intolerant to hydroxyurea. EHA Library. 2018;215071:PF628.
26. Curto-Garcia N, Baxter J, Harris E, et al. Molecular analysis in MAJIC PV correlation with clinical endpoints. HemaSphere. 2019;3(S1):740. doi: 10.1097/01.HS9.0000564676.68330.b5. DOI: https://doi.org/10.1097/01.HS9.0000564676.68330.b5